Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRX518 with Cyclophosphamide and Avelumab in Advanced Solid Tumors
NCT03861403Phase 1Terminated
- Sponsor
- Leap Therapeutics, Inc.
- Start
- May 2019
- Primary completion
- Jul 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of trx518 in solid tumor (advanced stage), triple-negative breast cancer (TNBC), hormone receptor-positive breast cancer and 2 more (6 arms), sponsored by Leap Therapeutics, Inc. Primary endpoints: Dose Limiting Toxicities, Recommended Phase 2 Dose and 1 more. Started May 2019; status: terminated.
02
Drugs
trx518
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)hormone receptor-positive breast cancermetastatic castration-resistant prostate cancer (mCRPC)ovarian cancer
Beyond the preview
Go deeper on NCT03861403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861403.